William Blair reissued their outperform rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a research report released on Thursday. William Blair also issued estimates for Sarepta Therapeutics’ Q3 2017 earnings at ($0.92) EPS, Q4 2017 earnings at ($1.02) EPS, FY2017 earnings at ($3.74) EPS, FY2018 earnings at ($2.76) EPS and FY2019 earnings at $0.43 EPS.

A number of other equities research analysts have also commented on SRPT. SunTrust Banks, Inc. raised Sarepta Therapeutics from a hold rating to a buy rating and increased their price target for the company from $30.00 to $30.97 in a research report on Wednesday, April 5th. Jefferies Group LLC reissued a hold rating and issued a $27.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, April 6th. Robert W. Baird reissued an outperform rating and issued a $102.00 price target on shares of Sarepta Therapeutics in a research report on Sunday, April 23rd. Vetr lowered Sarepta Therapeutics from a strong-buy rating to a buy rating and set a $37.67 price target for the company. in a research report on Monday, April 24th. Finally, Royal Bank Of Canada lowered their price target on Sarepta Therapeutics from $91.00 to $60.00 and set an outperform rating for the company in a research report on Friday, April 28th. Eight equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $61.28.

Sarepta Therapeutics (NASDAQ SRPT) traded up 1.15% during mid-day trading on Thursday, hitting $41.28. 138,208 shares of the stock were exchanged. The stock has a 50 day moving average price of $35.57 and a 200 day moving average price of $32.60. Sarepta Therapeutics has a 1-year low of $23.51 and a 1-year high of $63.73. The company’s market capitalization is $2.27 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. During the same quarter in the prior year, the business earned ($1.19) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% on a year-over-year basis. On average, equities analysts anticipate that Sarepta Therapeutics will post ($1.17) earnings per share for the current fiscal year.

WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/sarepta-therapeutics-inc-nasdaqsrpt-earns-outperform-rating-from-william-blair/1463695.html.

In other Sarepta Therapeutics news, CFO Sandesh Mahatme sold 50,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $2,050,000.00. Following the completion of the transaction, the chief financial officer now owns 41,736 shares in the company, valued at approximately $1,711,176. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Edward M. Md Kaye sold 10,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $410,000.00. Following the completion of the transaction, the director now owns 62,471 shares of the company’s stock, valued at approximately $2,561,311. The disclosure for this sale can be found here. In the last 90 days, insiders sold 78,056 shares of company stock valued at $3,224,208. 9.60% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of SRPT. Emerald Mutual Fund Advisers Trust increased its position in shares of Sarepta Therapeutics by 50.2% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 604,467 shares of the biotechnology company’s stock valued at $17,892,000 after buying an additional 201,942 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Sarepta Therapeutics by 63.9% in the first quarter. Russell Investments Group Ltd. now owns 38,273 shares of the biotechnology company’s stock valued at $1,133,000 after buying an additional 14,919 shares in the last quarter. Sigma Planning Corp increased its position in shares of Sarepta Therapeutics by 7.8% in the first quarter. Sigma Planning Corp now owns 12,895 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 930 shares in the last quarter. Columbus Circle Investors increased its position in shares of Sarepta Therapeutics by 175.0% in the first quarter. Columbus Circle Investors now owns 34,027 shares of the biotechnology company’s stock valued at $1,007,000 after buying an additional 21,652 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $388,000. Institutional investors and hedge funds own 64.28% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.